Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Accordingly, the drug–drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurth, Christian, Koskinen, Mikko, Fricke, Robert, Prien, Olaf, Korjamo, Timo, Graudenz, Kristina, Denner, Karsten, Bairlein, Michaela, von Bühler, Clemens-Jeremias, Wilkinson, Gary, Gieschen, Hille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828636/
https://www.ncbi.nlm.nih.gov/pubmed/31571146
http://dx.doi.org/10.1007/s13318-019-00577-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828636/
https://www.ncbi.nlm.nih.gov/pubmed/31571146
http://dx.doi.org/10.1007/s13318-019-00577-5

Ejemplares similares